Wockhardt Analyst Review May 2026

This Wockhardt analyst review for May 2026 covers the key data investors need for WOCKPHARMA at its current price of Rs 1,537.00. Wockhardt (NSE: WOCKPHARMA) is an Indian pharma company with a market capitalisation of approximately Rs 14,000 crore, known for its antibiotic resistance innovation platform and UK-Germany branded generics business. The analyst consensus target of Rs 1,900 implies meaningful upside, and this Wockhardt analyst review examines technical levels, business performance, valuation, and key risks that will determine whether WOCKPHARMA achieves that target through FY27.

Click Here – Get Free Investment Predictions

Wockhardt Company Snapshot May 2026

Wockhardt’s novel antibiotic WCK 5222 (Cefepime-Zidebactam) has received USFDA approval for drug-resistant infections, a potential blockbuster in the global antibiotic resistance crisis. This novel antibiotic pipeline is the key re-rating driver. The table below summarises the key data referenced in this Wockhardt analyst review.

Parameter	Value
NSE Ticker	WOCKPHARMA
Sector	Pharmaceuticals – Branded and Hospital
CMP (May 2026)	Rs 1,537.00
52 Week High	Rs 1,868.80
52 Week Low	Rs 1,086.70
Market Cap	Rs 14,000 Crore
Trailing P/E	35x
Analyst Consensus Target	Rs 1,900
Bull Case Target	Rs 2,400
Bear Case Target	Rs 1,200

Analyst Insight in This Wockhardt Analyst Review

Associate Director Kunal Singla suggests watching Wockhardt closely in May 2026. At Rs 1,537.00, Kunal Singla flags Pharmaceuticals – Branded and Hospital sector dynamics as the primary driver for WOCKPHARMA’s near-term price action. He notes support in the Rs 1108 to Rs 1460 zone and flags any sustained close above Rs 1629 as a positive signal worth tracking. Kunal Singla’s perspective on Wockhardt adds professional analysis to this Wockhardt analyst review and is not a buy recommendation.

Technical Analysis in This Wockhardt Analyst Review

At Rs 1,537.00, WOCKPHARMA is trading within its 52-week band of Rs 1,086.70 to Rs 1,868.80. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1108 to Rs 1460 band while resistance is seen in the Rs 1629 to Rs 1718 zone. A sustained move above Rs 1629 could open the path toward the analyst consensus target of Rs 1,900.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1108 to Rs 1460 – investors tracking this Wockhardt analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for WOCKPHARMA.
• Resistance Zone: Rs 1629 to Rs 1718 – a sustained close above Rs 1629 would be a positive breakout signal worth flagging in this Wockhardt analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,900 represents the base-case upside scenario identified in this Wockhardt analyst review.

Business Segment Analysis

Novel Antibiotics (WCK 5222 – First-in-Class)

This is the primary revenue and margin driver for Wockhardt, directly supporting the earnings trajectory toward the consensus target of Rs 1,900.

UK and Germany Branded Generic Pharmaceuticals

This segment adds scale and diversification to Wockhardt’s business model and is a meaningful EPS contributor through FY27 and FY28.

India Branded Formulations and Hospital Segment

This represents the medium-term growth frontier for Wockhardt and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Wockhardt Analyst Review

At Rs 1,537.00, Wockhardt trades at a trailing P/E of 35x. This Wockhardt analyst review presents three valuation scenarios: a bull case of Rs 2,400 on strong earnings delivery and sector tailwinds, a base case of Rs 1,900 at analyst consensus, and a bear case of Rs 1,200 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Wockhardt analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 2,400	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,900	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,200	Earnings miss or macro headwinds

Trade Outlook for Wockhardt

Based on the technical and fundamental analysis in this Wockhardt analyst review, investors might watch WOCKPHARMA near the support zone of Rs 1108 to Rs 1460 for potential opportunities. A flag above Rs 1629 could suggest improving momentum toward Rs 1,900. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Wockhardt in FY27

A well-rounded Wockhardt analyst review must assess downside risks. Key risks for Wockhardt include a macro slowdown affecting Pharmaceuticals – Branded and Hospital sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in WOCKPHARMA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Wockhardt Analyst Review Verdict for 2026

This Wockhardt analyst review concludes that at Rs 1,537.00, WOCKPHARMA offers a defined risk-reward with a consensus target of Rs 1,900. The 52-week range of Rs 1,086.70 to Rs 1,868.80 provides context on the current entry point. Use this Wockhardt analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on WOCKPHARMA.

Frequently Asked Questions: Wockhardt Analyst Review 2026

What is the analyst target for Wockhardt in 2026?

The analyst consensus target is Rs 1,900, with a bull case of Rs 2,400 and a bear case of Rs 1,200. Monitor Q1 FY27 earnings for confirmation as highlighted in this Wockhardt analyst review.

Is Wockhardt a good investment at Rs 1,537.00?

At Rs 1,537.00 with a P/E of 35x and a consensus target of Rs 1,900, this Wockhardt analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded and Hospital sector. Always consult a SEBI-registered advisor before investing.

What is Wockhardt’s 52-week high and low?

The 52-week high is Rs 1,868.80 and the 52-week low is Rs 1,086.70. At Rs 1,537.00, WOCKPHARMA is positioned within this range as noted in this Wockhardt analyst review.

What are the key risks for Wockhardt?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded and Hospital sector as assessed in this Wockhardt analyst review.

Where can I track live data for Wockhardt?

Track Wockhardt’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Wockhardt analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.